国药集团一致药业股份有限公司 2015 年第一季度报告全文
China National Accord Medicines Corporation Ltd.
First Quarterly Report 2015
April 2015
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord Medicines
Corporation Ltd. (hereinafter referred to as the Company) and its directors, supervisors and
senior executives should guarantee the reality, accuracy and completion of the quarterly
report, there are no any fictitious statements, misleading statements or important omissions
carried in this report, and shall take legal responsibilities, individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Yan Zhigang, person in charge of the Company, Wei Pingxiao, person in charger of
accounting works and Zhou Feifei, person in charger of accounting organ (accounting officer)
hereby confirm that the Financial Report of this Quarterly Report is authentic, accurate and
complete.
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section II. Main financial data and changes of shareholders
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□ Yes √No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 6,261,714,700.23 5,533,524,159.08 13.16%
Net profit attributable to shareholders of
197,026,237.82 167,818,387.39 17.40%
the listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting 192,315,542.07 165,006,263.57 16.55%
non-recurring gains and losses(RMB)
Net cash flow arising from operating
-425,683,165.96
activities(RMB) 182,179,606.70 142.80%
Basic earnings per share (RMB/Share) 0.543 0.582 -6.70%
Diluted earnings per share (RMB/Share) 0.543 0.582 -6.70%
Weighted average ROE 4.05% 7.21% -3.16%
Changes of this period-end
At the end of the reporting
At the end of last year over same period-end of last
period
year
Total assets (RMB) 13,399,261,901.35 12,828,941,540.90 4.45%
Net assets attributable to shareholder of
4,961,634,059.91 4,764,607,822.09 4.14%
listed company (RMB)
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Amount from year-begin to
Item Note
period-end
Gains/losses from the disposal of non-current asset (including the
-118,671.15
write-off that accrued for impairment of assets)
Governmental subsidy reckoned into current gains/losses (not Mainly due to follow money
including the subsidy enjoyed in quota or ration according to 5,091,842.57 received as: one million Yuan of
national standards, which are closely relevant to enterprise’s loan interest subsidy received
国药集团一致药业股份有限公司 2015 年第一季度报告全文
business) from Development and Finance
Bureau of Longhua New District
and Economic Services Bureau
by subsidiary of the Company,
the 0.9 million Yuan grants for
cefdinir and Cefaclor Suspension
project received from the Group,
the 674,600 Yuan of demolition
resettlement compensation for
old town received and 400000
Yuan special award for the
taxation; the patent award 300000
Yuan for year of 2013 received
from Shenzhen Market
Supervisory Authority, special
supporting fund 229000 Yuan for
the engineering lab of new-type
Cephalosporin, the 209600 Yuan
of the modern logistics public
information platform of the third
party, the special supporting
fund205300 Yuan of R&D
manufacture base for the drugs
etc.
Reversal of impairment reserve for account receivable with
8,430.00
separate impairment testing
Other non-operating income and expenditure except for the
663,591.41
aforementioned items
Less: impact on income tax 934,220.09
Impact on minority shareholders’ equity (post-tax) 276.99
Total 4,710,695.75 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Total common shareholders
14,356
at the end of report period
Top ten common shareholders
Amount of Number of share pledged/frozen
Shareholder’s Nature of Proportion of Amount of shares
restricted shares
name shareholder shares held held State of share Amount
held
Sinopharm State-owned
51.00% 184,942,291 74,482,543
Group Co., Ltd. legal person
National Social Domestic non
Security Fund state-owned legal 2.12% 7,700,000
116 combination person
National Social Domestic non
Security Fund state-owned legal 2.01% 7,298,555
106 combination person
HTHK/CMG
FSGUFP-CMG
Foreign
FIRST STATE 1.94% 7,032,720
Corporation
CHINA
GROWTH FD
BOC—Harvest
Domestic non
theme selected
state-owned 1.18% 4,274,694
mix securities
Corporation
investment fund
New China Life
Insurance Co.,
Ltd. – Bonus – Domestic non
Individual state-owned 1.16% 4,199,772
bonuses - Corporation
-018L-FH002
Shen
BOC-Harvest
Domestic non
research selected
state-owned 0.96% 3,489,967
stock securities
Corporation
investment fund
China Merchants
Foreign
Securities (HK) 0.94% 3,403,702
Corporation
Co., Limited
GUOTAI
JUNAN Foreign
0.92% 3,346,576
SECURITIES(H Corporation
ONGKONG)
国药集团一致药业股份有限公司 2015 年第一季度报告全文
LIMITED
China Life
Insurance Co.,
Ltd. – tradition – Domestic non
general insurance state-owned 0.83% 3,000,000
products - Corporation
005L-CT001
Shen
Top ten common shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Holding Co., Ltd. 110,459,748 110,459,748
shares
National Council for Social Security RMB ordinary
7,700,000 7,700,000
Fund-116 shares
National Council for Social Security RMB ordinary
7,298,555 7,298,555
Fund-106 shares
HTHK/CMG FSGUFP-CMG Domestically
FIRST STATE CHINA GROWTH 7,032,720 listed foreign 7,032,720
FD shares
BOC—Harvest theme selected mix RMB ordinary
4,274,694 4,274,694
securities investment fund shares
New China Life Insurance Co., Ltd.
RMB ordinary
– Bonus – Individual bonuses - 4,199,772 4,199,772
shares
-018L-FH002 Shen
BOC-Harvest research selected RMB ordinary
3,489,967 3,489,967
stock securities investment fund shares
Domestically
China Merchants Securities (HK)
3,403,702 listed foreign 3,403,702
Co., Limited
shares
GUOTAI JUNAN Domestically
SECURITIES(HONGKONG) 3,346,576 listed foreign 3,346,576
LIMITED shares
China Life Insurance Co., Ltd. –
RMB ordinary
tradition – general insurance 3,000,000 3,000,000
shares
products - 005L-CT001 Shen
BOC—Harvest theme selected mix securities investment fund and BOC-Harvest research
Explanation on associated selected stock securities investment fund have the same custodian as Harvest Fund
relationship among the aforesaid Management Co., Ltd.; it is unknown that there exists no associated relationship or belongs to
shareholders the consistent actionist among the other tradable shareholders regulated by the Management
Measure of Information Disclosure on Change of Shareholding for Listed Companies.
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1. Other account receivables: increased 10.45 million Yuan over that of balance at period-begin with growth rate of 36.58%, mainly
because the increase of housing lease, deposit, margin and etc. in the Period;
2. Other current assets: decreased 27.86 million Yuan over that of balance at period-begin with growth rate of -69.13%, mainly
because the retained VAT decreased in the Period;
3. Short-term loans: increased 494.71 million Yuan over that of balance at period-begin with growth rate of 32.59%, mainly because
supply chain financing increased in the Period;
4. Account received in advance: decreased 22.77 million Yuan over that of balance at period-begin with growth rate of -56.45%,
mainly because the account paid in advance for the goods from merchants declined in the Period;
5. Wages payable: decreased 69.16 million Yuan over that of balance at period-begin with growth rate of -40.22%, mainly because
the remuneration, accrual last year, has distributed in this Period;
6. Tax payable: increased 3,414 Yuan over that of balance at per| 国药集团一致药业股份有限公司2015年第一季度报告全文（英文版） （下载公告） |
|---|
| 公告日期:2015-04-24 |
|
|
| 附件：公告原文 |
| ↑返回页顶↑ |